High insurance denial rates for breakthrough hepatitis drugs

Author(s):

denial rates hepatitis drugs

Insurance denial rates for direct-acting antiviral drugs used to treat hepatitis C are high—more than 50% for those with private insurance—according to a study in Open Forum Infectious Diseases. The drugs have been a game-changer in saving patients lives.

Read more via Penn Medicine News and access the study at Oxford Academic.

LEAVE A REPLY

Please enter your comment!
Please enter your name here